GR2301
/ Genrix Bio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
June 15, 2026
A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
New P1 trial
June 15, 2026
GREVIT: A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo
(clinicaltrials.gov)
- P1/2 | N=116 | Not yet recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
New P1/2 trial • Dermatology • Immunology • Vitiligo
September 25, 2025
A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.
New P1 trial
1 to 3
Of
3
Go to page
1